Cargando…

Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes

Aims: The role of hypertriglyceridemia in stroke is poorly understood. The Pemafibrate for Prevention of Atherosclerotic Diseases in Stroke (PPAR Stroke) study was designed to assess the effects of a novel selective peroxisome proliferator-activated receptor alpha modulator, pemafibrate, on vascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoshino, Takao, Ishizuka, Kentaro, Toi, Sono, Seki, Misa, Kitagawa, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252640/ https://www.ncbi.nlm.nih.gov/pubmed/34248089 http://dx.doi.org/10.5551/jat.63036

Ejemplares similares

Recurrent Stroke Incidence and Etiology in Patients with Embolic Stroke of Undetermined Source and Other Stroke Subtypes
por: Toi, Sono, et al.
Publicado: (2022)

Localization of Infratentorial Lesion could Predict Patent Foramen Ovale as an Etiology in Embolic Stroke of Undetermined Source
por: Ishizuka, Kentaro, et al.
Publicado: (2022)

Triglyceride-glucose index as a prognostic marker after ischemic stroke or transient ischemic attack: a prospective observational study
por: Hoshino, Takao, et al.
Publicado: (2022)

Characteristics and Prognosis of Stroke in Living Donor Renal Transplant Recipients
por: Mizuno, Takafumi, et al.
Publicado: (2022)

Hyperhomocysteinemia Increases Vascular Risk in Stroke Patients with Chronic Kidney Disease
por: Mizuno, Takafumi, et al.
Publicado: (2023)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
por: Bando, Hidenori, et al.
Publicado: (2021)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation
por: Maruyama, Kenji, et al.
Publicado: (2017)

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia
por: Hida, Yuki, et al.
Publicado: (2023)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome
por: Iwakura, Tomohiro, et al.
Publicado: (2023)

Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial
por: Ishizuka, Kentaro, et al.
Publicado: (2022)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2021)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Diagnostic Utility of Polymerase Chain Reaction for Paraffin-embedded Sinus Specimens for Rhinocerebral Mucormycosis Complicated by Internal Carotid Artery Thrombosis and Cerebral Infarction
por: Maeda, Yukiko, et al.
Publicado: (2021)

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
por: Ikeda, Suguru, et al.
Publicado: (2021)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease
por: Imai, Enyu, et al.
Publicado: (2022)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
por: Yokote, Koutaro, et al.
Publicado: (2021)

Hypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke?
por: Liang, Hai-jie, et al.
Publicado: (2022)

Hypertriglyceridemia
por: Brahm, Amanda, et al.
Publicado: (2013)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
por: Amioka, Naofumi, et al.
Publicado: (2022)

Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates
por: Masuda, Daisaku
Publicado: (2023)

Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS)
por: Uchiyama, Shinichiro, et al.
Publicado: (2015)

Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model
por: Tomita, Yohei, et al.
Publicado: (2019)

SAT-578 A Rare Case of Laboratory Hypertriglyceridemia: Glycerol Kinase Deficiency
por: Ueda, Masako, et al.
Publicado: (2020)

The association of parameters of body composition and laboratory markers with the severity of hypertriglyceridemia-induced pancreatitis
por: Chen, Lifang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uoj4agiq2mqegvog7t2947nerd